

Mye oma

HYDRASHIFT *avoids* *daratumumab* *interference* on **IMMUNOFIXATION**

Ordering information

Instrument

- HYDRASYS 2 Scan Focusing1202

Accessories

- HYDRASHIFT 2/4 Accessories
(Applicator carrier specific for HYDRASHIFT)1251

Controls/ Calibrators


- daratumumab control4765

Consumables

- Applicators Green HYDRASHIFT
(10 individual Applicators green)4195

Reagents

- HYDRASHIFT 2/4 daratumumab
(20 tests)4639
- HYDRAGEL 2 IF Acid violet
Dynamic Mask4302
- HYDRAGEL 4 IF Acid violet
Dynamic Mask4304
- Antisera and Fixative for immunofixation IF
Dynamic Mask4315
- HYDRAGEL 2 IF Acid violet
Standard Mask4802
- HYDRAGEL 4 IF Acid violet
Standard Mask4804
- Antisera and Fixative for immunofixation IF
Standard Mask4815



Sebia | RCS Evry 672 041 902 | Parc technologique Léonard de Vinci | 27, rue Léonard de Vinci | CP 8010 Lisses | 91008 Evry cedex | France | Tel.: +33 1 69 89 80 80 | E-mail: sebia@sebia.com | www.sebia.com

Benelux | Tel: +32 2 702 64 64 (BE) | Tel: +31 20 610 8099 (NL) | E-mail: sebia.benelux@sebia.com • **Brasil** | Tel: +55 11 3849 0148 | E-mail: brasil@sebia.com
Canada | Tel: +1 (888) 725-3013 | Fax: +1 (438) 380-3780 | E-mail: canada@sebia.com • **China** | Tel: +86 (21) 6360 1436 | Fax: +86 (21) 6361 2011 | E-mail: china@sebia.com • **Germany & Austria** | Tel: +49 (0) 661 33081 | Fax: +49 (0) 661 31881 | E-mail: sebia@sebia.de • **India** | Tel: +91 124 4262100 | E-mail: sebiaindia@sebia.com • **Italy** | Tel: +39 055 24851 | Fax: +39 055 0982083 | E-mail: info@sebia.it • **Japan** | Tel: (03) 5830-0139 | Fax: (03) 5830-0140
Portugal | Tel: +351 211 224 653 | Fax: +351 211 305 079 | E-mail: portugal@sebia.com • **Spain** | Tel: +34 93 208 15 52 | Fax: +34 93 458 55 86 | E-mail: sebia@sebia.es • **Singapore** | Tel: +65 6223 2273 | E-mail: singapore@sebia.com • **Switzerland** | Tel: +41 44 787 88 10 | E-mail: contact.ch@sebia.com
UK | Tel: +44 (0)1276 600636 | Fax: +44 (0)1276 38827 | E-mail: sales@sebia.co.uk • **UAE** | Tel: +971 (0)4 878 69 77 • **USA** | Tel: +1 (770) 446-3707 - Fax: +1 (770) 446-8511 | E-mail: info@sebia-usa.com

©2021 Sebia - Non-contractual illustration - 07/2021 - Ref: HSDBIEN - Sebia reserves the right to modify at any time and without notice the information contained in this document intended for healthcare professionals. This document contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Carefully read the instructions in the reagent package inserts and instrument manuals.

sebia
The new language of life

What is DARZALEX®

DARZALEX® (daratumumab) is a human monoclonal antibody (mAb) targeting CD38 used in Multiple Myeloma (MM) treatment regimens.

IF is one of the tests referenced in the IMWG guidelines to assess response to treatment in a patient with MM.



Treatments with mAb can affect the interpretation on immunofixation (IF) tests.



HYDRASHIFT avoids daratumumab interference on IF


HYDRASHIFT daratumumab is a unique «shift» technology to avoid daratumumab interference using HYDRAGEL 2/4 on HYDRASYS 2 platforms.

Easy to implement: no sample pre-treatment, same IF protocol.



Clinical case example

Laura B.
 Date of Birth: December 23th, 1948
 Pathology: Multiple Myeloma
 Serum Peak: IgG Kappa (κ)
 Urine Peak: Free Light Chain Kappa



* Contact your Sebia representative for other regulatory approvals